

Development of an ADC therapeutic candidate targeting the novel antigen *** for the treatment of solid tumors



ONCOLOGY	Candidate
Product Type	Antibody
Indication	Solid tumor including HCC and SCLC
Target	***
MoA(Mechanism of Action)	Monoclonal antibody targeting a tumor-specific antigen *** delivers a potent cytotoxic drug directly to cancer cells.
Competitiveness	First-in-class ADC. Currently, there is no competition in ADC modality.
Development Stage	Candidate
Route of Administration	IV (planned)

Any unauthorized distribution or reproduction of this material is strictly prohibited.